FDA Determines Regulatory Review Period for FERAHEME Patent Extension

Summary

The Food and Drug Administration (FDA) has officially confirmed the regulatory review period for FERAHEME, a human drug product, as required by law, following a patent extension application submitted to the Director of Patents and Trademarks at the Department of Commerce.